GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results